1
Clinical Trials associated with COVID-19 trimeric S-protein subunit vaccine(trivalent)(Clover Biopharmaceuticals AUS)Phase 3, Multi-center, Observer-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of SCB-2023 Vaccine Administered as a Booster Dose to Adults Who Previously Received COVID-19 Vaccine
The purpose of this study is to assess the immunogenicity and safety of SCB-2023 trivalent vaccine compared to the prototype SCB-2019 monovalent vaccine in participants previously vaccinated with 3 doses of inactivated COVID-19 vaccine ≥6 months prior to enrollment.
100 Clinical Results associated with COVID-19 trimeric S-protein subunit vaccine(trivalent)(Clover Biopharmaceuticals AUS)
100 Translational Medicine associated with COVID-19 trimeric S-protein subunit vaccine(trivalent)(Clover Biopharmaceuticals AUS)
100 Patents (Medical) associated with COVID-19 trimeric S-protein subunit vaccine(trivalent)(Clover Biopharmaceuticals AUS)
100 Deals associated with COVID-19 trimeric S-protein subunit vaccine(trivalent)(Clover Biopharmaceuticals AUS)